Kemal Kürbüz

Kemal Kürbüz

Auto-generated profile, based on publicly available information

Kemal Kürbüz

Department of Gastroenterology, Health Sciences Unıversity, Ümraniye Training and Research Hospital, İstanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
SSSüleyman Sayar
Süleyman Sayar
KKKemal Kürbüz
Kemal Kürbüz
RKResul Kahraman
Resul Kahraman
OÖOğuzhan Öztürk
Oğuzhan Öztürk
ZÇZuhal Çalışkan
Zuhal Çalışkan
KÖKamil Özdil
Kamil Özdil
Background/Aims: Hepatitis B reactivation (HBVR) is an important risk of treatment with tumor necrosis factor inhibitors (anti-TNF). While antiviral prophylaxis is recommended before treatment in HBsAg-positive patients, there is no clear approach for the follow-up or prophylactic treatment of patients with past hepatitis B virus (HBV) infection. The aim of this study was to evaluate patients with past HBV infection treated with anti-TNF for HBVR and/or HBVR-associated biochemical breakthrough. Material and Methods: Patients who received anti-TNF therapy and had past HBV infection (HBsAg negative, anti-HBc IgG positive, anti-HBs negative or positive) were screened and evaluated at 3-month intervals for viral and biochemical breakthrough according to a liver function test (ALT) and HBV DNA level. Results: A total of 653 patients who received anti-TNF therapy were screened. Ninety of these patients had past HBV infection and had not received antiviral prophylaxis. Anti-HBs positivity and isolated anti-HBc IgG positivity were seen in 87.7% (n: 79) and 12.2% (n: 11) of these patients, respectively. No HBVR was seen in 20% (n: 18) of patients who were followed up regularly, and no HBVR-associated biochemical breakthrough was found in patients who were not followed up regularly in terms of HBV DNA level (80%, n: 72) during the follow-up period (26±16 months). Conclusion: The use of anti-TNF in patients with past HBV infection has a low risk for HBVR. A follow-up for the ALT and HBV DNA levels at 3-month intervals may be more reasonable than administering antiviral prophylaxis to all patients.

15 July 2021 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
SSSüleyman Sayar
Süleyman Sayar
HAHüseyin Aykut
Hüseyin Aykut
ÖKÖzkan Kaya
Özkan Kaya
KKKemal Kürbüz
Kemal Kürbüz
ÇAÇağatay Ak
Çağatay Ak
KÖKâmil Özdil
Kâmil Özdil
Background: The aim of this study was to evaluate the prevalence of osteopenia and osteoporosis in adult patients with celiac disease (CD) at diagnosis and/or in the follow-up after a gluten-free diet (GFD). Methods: Adult patients diagnosed with CD were retrospectively screened through follow-up records and computer databases. Patients assessed by dual-energy X-ray absorptiometry (DEXA) at diagnosis and/or in the follow-up after a GFD were included in the study. Results: One hundred patients who underwent a DEXA scan at least once after diagnosis or after being on a GFD were included in the study. The mean age of the patients at diagnosis was 34.61 ± 10.3 years, and 84% of the patients (n = 84) were female. At the time of diagnosis (n = 46), the prevalence of osteopenia and osteoporosis was 67.3% and 15.2%, respectively, at the lumbar spine, and 43.4% and 10.8%, respectively, at the femur. After a GFD (n = 78), the prevalence of osteopenia and osteoporosis was 61.5% and 8.9%, respectively, at the lumbar spine, and 37.1% and 2.5%, respectively, at the femur. Conclusion: The prevalence of CD patients with low bone mineral density (BMD) is high after diagnosis and in the follow-up after a GFD. It is important for all patients with CD to undergo a DEXA scan to determine the follow-up and/or treatment characteristics. Cite this article as: Sayar S, Aykut H, Kaya Ö, et al. Bone mineral density screening and the frequency of osteopenia/osteoporosis in Turkish adult patients with Celiac disease. Turk J Gastroenterol. 2021; 32(7): 600-607.

1 August 2020 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
SSSüleyman Sayar
Süleyman Sayar
RARoni Atalay
Roni Atalay
ŞÇŞüheda Çakmak
Şüheda Çakmak
GAGülçiçek Ayrancı
Gülçiçek Ayrancı
KKKemal Kürbüz
Kemal Kürbüz
HDHamdi Levent Doganay
Hamdi Levent Doganay